Humacyte 경영진
경영진 기준 점검 1/4
Humacyte CEO는 Laura Niklason, Jan2004 에 임명되었습니다 의 임기는 22.58 년입니다. 총 연간 보상은 $5.23M, 12.1% 급여 및 87.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $151.95K 가치에 해당하는 회사 주식의 0.09% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 1.6 년과 5 년입니다.
핵심 정보
Laura Niklason
최고경영자
US$5.2m
총 보수
| CEO 급여 비율 | 12.10% |
| CEO 재임 기간 | 22.6yrs |
| CEO 지분 보유율 | 0.09% |
| 경영진 평균 재임 기간 | 1.6yrs |
| 이사회 평균 재임 기간 | 5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jul 24
HUMA: V012 Phase 3 Data Will Drive Dialysis Access Opportunity
Humacyte's updated analyst price target of $4.00, along with shifts in fair value and key assumptions such as discount rate, revenue growth, profit margin, and future P/E, reflects analysts' response to recent positive V012 Phase 3 interim data, evolving indication expansion expectations, and refreshed long term revenue projections across dialysis and vascular applications. Analyst Commentary Recent research coverage on Humacyte highlights a mix of optimism around the V012 Phase 3 interim data, expectations for regulatory progress, and ongoing adjustments to revenue and indication assumptions.
내러티브 업데이트 • Jul 10
HUMA: V012 Phase 3 Dialysis Data Will Drive Future Repricing
Humacyte's updated analyst price targets, which now range from $1.25 to $4.00, reflect mixed revisions as analysts weigh positive interim V012 data and potential AV access indication expansion against updated assumptions for growth, profitability, and future P/E expectations. Analyst Commentary on Humacyte Recent street research on Humacyte reflects a wide range of expectations, with some analysts trimming price targets even as they acknowledge positive interim V012 data and potential indication expansion in dialysis access.
내러티브 업데이트 • Jun 26
HUMA: V012 Dialysis Data Will Shape Future Indication Expansion Prospects
Analysts have reset Humacyte’s fair value estimate from $7.86 to $2.05, citing updated assumptions on growth, margins, and long term P/E in light of recent price target revisions that reflect both encouraging V012 data and moderated expectations for the company’s acellular vessel portfolio. Analyst Commentary Recent Street research on Humacyte highlights mixed views, with some analysts leaning optimistic on the acellular vessel opportunity and others resetting expectations, which collectively helps explain the lower fair value estimate.Seeking Alpha • Feb 09
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist
Summary Humacyte, Inc. remains rated Hold despite a DoD funding catalyst revealed today, as commercial traction for Symvess is not yet proven. Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Read the full article on Seeking Alpha분석 기사 • Sep 19
Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 21
Is Humacyte (NASDAQ:HUMA) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Mar 24
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Summary Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious, with high operating expenses and a cash runway extending only into late 2025, raising concerns about future dilution. Given these challenges, I downgrade HUMA to "Sell," as achieving a return on investment for Symvess seems unlikely without significant financial strain. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
Summary Humacyte, Inc. arrived on the Nasdaq in 2021 via a SPAC deal and reappeared on my radar after the Symvess approval in vascular trauma repair. Platform enabling off-the-shelf bioengineered tissues could transform the field of regenerative medicine. There's a large addressable market across 3 lead indications alone (trauma, dialysis & PAD) + significant optionality for more complex projects (i.e., biovascular pancreas in diabetes). Key concerns include slow launch out of the gate, continued cash burn & dilution, competition, and manufacturing capacity. My Action Plan: I remain on the sidelines for HUMA stock and will continue to monitor launch metrics as well as pipeline progress. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Summary Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its market potential is limited, and adoption is expected to be slow and costly. Phase 3 trial data for ATEVs in hemodialysis patients showed higher thrombosis and infection rates, raising concerns about its safety and efficacy. Humacyte's financial situation remains precarious, with high operating expenses and potential ongoing dilution, leading to a downgrade on HUMA stock from "buy" to "hold". Read the full article on Seeking AlphaSeeking Alpha • Dec 14
Humacyte: FDA Waiting Game Bleeding Company Dry
Summary Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong clinical data, the FDA's postponement of the ATEV approval has left Humacyte in a precarious financial position, forcing it to raise ~$45m since August. The lack of a clear FDA timeline creates significant risk for investors, leading to a downgrade from "buy" to "hold" due to potential further delays. The market opportunity for ATEVs remains uncertain, questioning whether Humacyte stock can achieve significant upside even if FDA approval is granted. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Summary Humacyte’s acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma. Risks include potential FDA rejection, financial distress, and management's recent share sales, which warrant cautious investment consideration. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$97m |
| Mar 31 2026 | n/a | n/a | -US$95m |
| Dec 31 2025 | US$5m | US$634k | -US$41m |
| Sep 30 2025 | n/a | n/a | -US$37m |
| Jun 30 2025 | n/a | n/a | -US$59m |
| Mar 31 2025 | n/a | n/a | -US$78m |
| Dec 31 2024 | US$905k | US$612k | -US$149m |
| Sep 30 2024 | n/a | n/a | -US$153m |
| Jun 30 2024 | n/a | n/a | -US$140m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$3m | US$604k | -US$111m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$2m | US$500k | -US$12m |
| Sep 30 2022 | n/a | n/a | US$34m |
| Jun 30 2022 | n/a | n/a | US$28m |
| Mar 31 2022 | n/a | n/a | -US$26m |
| Dec 31 2021 | US$11m | US$500k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$85m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$619k | US$75k | -US$67m |
보상 대 시장: Laura의 총 보수(USD5.23M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.50M)보다 높습니다.
보상과 수익: Laura의 보상은 회사가 적자임에도 증가했습니다.
CEO
Laura Niklason (63 yo)
22.6yrs
재임 기간
US$5,234,908
보수
Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 22.6yrs | US$5.23m | 0.090% $ 152.0k | |
| CFO, Chief Corporate Development Officer & Treasurer | 5.8yrs | US$2.13m | 0.056% $ 94.9k | |
| Chief Medical Officer | 4.3yrs | US$2.10m | 0.043% $ 73.0k | |
| Chief People Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Strategy Officer | 1.6yrs | 데이터 없음 | 데이터 없음 | |
| Chief Quality & Regulatory Officer | 1.6yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Business Development | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Surgical Officer | less than a year | 데이터 없음 | 데이터 없음 |
1.6yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 관리: HUMA의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.6 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 22.6yrs | US$5.23m | 0.090% $ 152.0k | |
| Independent Director | 21.2yrs | US$207.80k | 0.024% $ 40.2k | |
| Director | 21.6yrs | US$202.80k | 0% $ 0 | |
| Independent Director | 5yrs | US$207.80k | 0% $ 0 | |
| Independent Chairman of the Board | 10.9yrs | US$227.80k | 0.055% $ 92.2k | |
| Independent Director | 5yrs | US$210.30k | 0.016% $ 27.4k | |
| Independent Director | 4.2yrs | US$202.80k | 0% $ 0 | |
| Independent Director | 5yrs | US$202.80k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$202.80k | 0.0031% $ 5.2k | |
| Independent Director | 2.2yrs | US$202.80k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$202.80k | 0% $ 0 |
5.0yrs
평균 재임 기간
67yo
평균 나이
경험이 풍부한 이사회: HUMA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/17 18:23 |
| 종가 | 2026/08/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Humacyte, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Miksic | Barclays |
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |